The G2 checkpoint—a node‐based molecular switch
Mark C. de Gooijer(Manchester Academic Health Science Centre), Olaf van Tellingen(The Netherlands Cancer Institute), Arnout van den Top(The Netherlands Cancer Institute), Irena Bočkaj(University of Groningen), Jos H. Beijnen(The Netherlands Cancer Institute), Thomas Würdinger(Amsterdam University Medical Centers)
Cited by 58
Related Papers
The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions
|The Journal of Experimental Medicine|2007|2.3k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
|PubMed|2002|507
miR-296 Regulates Growth Factor Receptor Overexpression in Angiogenic Endothelial Cells
|Cancer Cell|2008|476
Clinical Pharmacokinetics of Cyclophosphamide
|Clinical Pharmacokinetics|2005|451